Lantheus Holdings LNTH Reportable — Other Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lantheus Holdings in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lantheus Holdings's reportable — other research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lantheus Holdings's reportable — other research and development expense?
- Lantheus Holdings (LNTH) reported reportable — other research and development expense of $27.59M in Q1 2026.
- How has Lantheus Holdings's reportable — other research and development expense changed year-over-year?
- Lantheus Holdings's reportable — other research and development expense decreased by 1.1% year-over-year, from $27.89M to $27.59M.
- What is the long-term trend for Lantheus Holdings's reportable — other research and development expense?
- Over 3 years (2022 to 2025), Lantheus Holdings's reportable — other research and development expense has grown at a -23.6% compound annual growth rate (CAGR), from $303.5M to $135.15M.
- What does reportable — other research and development expense mean?
- This metric captures all research and development expenditures within the reportable segment that are not classified as software development or acquired in-process research costs. It typically encompasses clinical trial expenses, laboratory supplies, personnel costs for scientific staff, and other operational outlays necessary for product innovation. Monitoring this figure provides insight into the baseline recurring investment required to sustain the company's pipeline of diagnostic and therapeutic products.